Filtyp
Åsa Petersén - clinician scientist Important paper on Huntington disease by Gabery et al in Acta Neuropathologica 2021 TNU research The Translational Neuroendocrine Research Unit (TNU) focuses on Huntington’s disease (HD) and the spectrum of amyotrophic lateral sclerosis (ALS) and the behavioural variant of frontal temporal dementia (bvFTD).These are fatal neurodegenerative disorders without effec
https://www.huntington-research.lu.se/landing-page - 2025-01-17
Wagner L1,2,3, Wolf R2, Zeitschel U4, Rossner S4, Petersén Å5, Leavitt BR6, Kästner F7, Rothermundt M7,8, Gärtner UT2, Gündel D9, Schlenzig D3, Frerker N10, Schade J10, Manhart S2, Rahfeld JU1,3, Demuth HU3 and von Hörsten S10.1Deutschsprachige Selbsthilfegruppe für Alkaptonurie (DSAKU) e.V., Stuttgart, Germany.2Probiodrug AG, Halle, Germany.3Fraunhofer-Institute for cell therapy and immunology, D
Our team of highly skilled staff has long experience in translational research. Visit us Find your way to us in Lund. Åsa Petersén Group leader, Professor Email: Asa [dot] Petersen [at] med [dot] lu [dot] se Telephone: +46 46 222 16 86 Sanaz Gabery Guest researcher Email: Sanaz [dot] Rasoly_Gabery [at] med [dot] lu [dot] se Sofia Bergh PhD student Email: Sofia [dot] Bergh [at] med [dot] lu [dot] s
https://www.huntington-research.lu.se/team - 2025-01-17
Lilja Andersson P1, Petersén Å1, Graff C2 and Edberg A-K3.1Lund University, Sweden2Karolinska Institute, Sweden 3Kristianstad University, SwedenNursing Ethics. Apr 21 (2015)AbstractBackground: A predictive genetic test for Huntington’s disease can be used before any symptoms are apparent, but there is only sparse knowledge about the long-term consequences of a positive test result. Such knowledge
https://www.huntington-research.lu.se/ethical-aspects-predictive-test-huntingtons-disease-long-term-perspective - 2025-01-17
Gabery S, Halliday G, Kirik D, Englund E, Petersén Å.Neuropathol Appl Neurobiol. 41(6): 843-848 (2015)No abstract available.Full text article - on Wiley's website
Gabery S1, Georgiou-Karistianis N2, Lundh SH1, Cheong RY1, Churchyard A3, Chua P4, Stout JC2, Egan GF5, Kirik D6 and Petersén Å1.1Translational Neuroendocrine Research Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden.2School of Psychological Sciences, Monash University, Clayton, Victoria, 3180, Australia.3School of Psychological Sciences, Monash University, Clayton,
https://www.huntington-research.lu.se/volumetric-analysis-hypothalamus-huntington-disease-using-3t-mri-image-hd-study - 2025-01-17
Breimer P, Petersén Å and Widner H. Lakartidningen. 2021;118:20126. (2021) Abstract Huntington disease (HD) is a progressive neurodegenerative disorder caused by an expanded CAG repeat in the huntingtin gene. It is inherited in an autosomal dominant fashion with full penetrance. Around 15% of cases arise from spontaneous expansion of the CAG repeat. The clinical presentation includes involuntary m
https://www.huntington-research.lu.se/recurrent-psychotic-symtoms-over-several-years-were-caused-huntingtonsdisease - 2025-01-17
Wiesner D, Sinniger J, Henriques A, Dieterlé S, Müller H, Rasche V, Ferger B, Dirrig-Grosch S, Soylu-Kucharz R, Petersén A, Walther P, Linkus B, Kassubek J, Wong PC, Ludolph AC and Dupuis L.Human Molecular Genetics 24(8): 2228-2240 (2015)AbstractMutations in components of the molecular motor dynein/dynactin lead to neurodegenerative diseases of the motor system or atypical parkinsonism. These muta
Cheong RY, Baldo B, Sajjad MU, Kirik D and Petersén Å. Neuropathology and Applied Neurobiology. 47(4): 564-578 (2021) doi: 10.1111/nan.12682. Abstract Aims: Huntington disease (HD) is a fatal neurodegenerative disorder with no disease-modifying treatments approved so far. Ongoing clinical trials are attempting to reduce huntingtin (HTT) expression in the central nervous system (CNS) using differen
Petersén is head of the Huntington Disease Center and the clinical multi-professional HD team at the HD Clinic, located at the Neurology department at Skåne University Hospital (SUS) in Lund. The HD Center was formed at LU and Region Skåne with the aim to improve healthcare for families with HD and to bring research closer to the clinic. Please see www.huntingtoncentrum.se for more information. Th
https://www.huntington-research.lu.se/patients - 2025-01-17
Gabery S, Ahmed RA, Caga J, Kiernan MC, Halliday GM and Petersén Å. Neuropathology and Applied Neurobiology. 47(7): 979-989 (2021) doi.org/10.1111/nan.12709 Abstract Aims To determine the underlying cellular changes and clinical correlates associated with pathology of the hypothalamus in amyotrophic lateral sclerosis (ALS), as hypothalamic atrophy occurs in the preclinical phase of the disease.
Baldo B, Cheong RY, Petersén ÅPLoS One 9(10) (2014)AbstractPsychiatric and metabolic features appear several years before motor disturbances in the neurodegenerative Huntington’s disease (HD), caused by an expanded CAG repeat in the huntingtin (HTT) gene. Although the mechanisms leading to these aspects are unknown, dysfunction in the hypothalamus, a brain region controlling emotion and metabolism
Soylu-Kucharz R, Khoshnan A and Petersén Å. bioRxiv 2021.04.08.438894; First published April 9, 2021. https://doi.org/10.1101/2021.04.08.438894 Abstract Background Huntington’s disease (HD) is a neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin (HTT) gene. Metabolic changes are associated with HD progression, and underlying mechanisms are not fully known. As the IKKβ/NF
Henningsen JB, Soylu-Kucharz R, Björkqvist M and Petersén Å. Heliyon. 2021 Aug 14;7(8):e07808. doi: 10.1016/j.heliyon.2021.e07808. eCollection 2021 Aug. Abstract Huntington disease (HD) is a fatal neurodegenerative movement disorder caused by an expanded CAG repeat in the huntingtin gene (HTT). The mutant huntingtin protein is ubiquitously expressed, but only certain brain regions are affected. T
https://www.huntington-research.lu.se/effects-excitotoxicity-hypothalamus-transgenic-mouse-models-huntington-disease - 2025-01-17
Learn more from these short films where Åsa Petersén talks about cognitive symptoms and behavioural changes and psychiatric in Huntington's disease. Published by courtesy of Riksförbundet Huntingtons Sjukdom. All films are in Swedish. To view the Swedish subtitles, please click the button "CC" in the control bar (third from right) and choose "Svenska". Åsa Petersén about cognitive symptoms. Åsa
https://www.huntington-research.lu.se/cognitive-symptoms-and-behavioural-changes - 2025-01-17
Gabery S, Kwa JE, Cheong RY, Baldo B, Ferrari Bardile C, Tan B, McLean C, Georgiou-Karistianis N, Poudel GR, Halliday G, Pouladi MA and Petersén Å. Acta Neuropathologica. 142(5): 791-806 (2021) doi: 10.1007/s00401-021-02362-8. Abstract Huntington disease (HD) is a fatal neurodegenerative disorder caused by an expanded CAG repeat in the huntingtin (HTT) gene. The typical motor symptoms have been a
https://www.huntington-research.lu.se/early-white-matter-pathology-fornix-limbic-system-huntington-disease - 2025-01-17
Hyrskyluoto A, Bruelle C, Lundh SH, Do HT, Kivinen J, Rappou E, Reijonen S, Waltimo T, Petersén Å, Lindholm D and Korhonen L.Human Molecular Genetics 23: 5928-5939 (2014)AbstractHuntington's disease (HD) is an autosomal inherited neurological disease caused by a CAG repeat expansion in the first exon of huntingtin gene encoding for the huntingtin protein (Htt). In HD there is an accumulation of in
Dickson E, Soylu-Kucharz R , Petersén Å and Björkqvist M. Mol Metab. 2022 Mar;57:101439. doi: 10.1016/j.molmet.2022.101439. Epub 2022 Jan 7. Abstract Objective In Huntington's disease (HD), the disease-causing huntingtin (HTT) protein is ubiquitously expressed and causes both central and peripheral pathology. In clinical HD, a higher body mass index has been associated with slower disease progress
Soylu-Kucharz R, Khoshnan A and Petersén Å. iScience 2022 Jan 19;25(2):103771. doi: 10.1016/j.isci.2022.103771. eCollection 2022 Feb 18. Abstract Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin (HTT) gene. Metabolic changes are associated with HD progression, but underlying mechanisms are not fully known. As the IKKβ/NF-κB pathway is an
Dickson E, Sai Dwijesha A, Andersson N, Lundh S, Björkqvist M, Petersén Å and Soylu-Kucharz R. Frontiers in Neuroscience. 2022 Nov 3;16:1027269. doi: 10.3389/fnins.2022.1027269. PMID: 36408416; PMCID: PMC9671106. Abstract Structural changes and neuropathology in the hypothalamus have been suggested to contribute to the non-motor manifestations of Huntington’s disease (HD), a neurodegenerative diso
